Stock of the Day: China Cord Blood Corp Can’t Be More Risky. Just Reaches 52-Week Low

Stock of the Day: China Cord Blood Corp Can't Be More Risky. Just Reaches 52 Week Low

The stock of China Cord Blood Corp (NYSE:CO) hit a new 52-week low and has $4.15 target or 10.00% below today’s $4.61 share price. The 6 months bearish chart indicates high risk for the $360.31 million company. The 1-year low was reported on Oct, 17 by If the $4.15 price target is reached, the company will be worth $36.03 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 40,672 shares traded hands or 62.05% up from the average. China Cord Blood Corp (NYSE:CO) has declined 16.92% since March 14, 2016 and is downtrending. It has underperformed by 22.53% the S&P500.

China Cord Blood Corp (NYSE:CO) Ratings Coverage

Out of 2 analysts covering China Cord Blood (NYSE:CO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. China Cord Blood has been the topic of 4 analyst reports since August 21, 2015 according to StockzIntelligence Inc. Roth Capital maintained the stock with “Hold” rating in Friday, August 28 report. TH Capital maintained it with “Neutral” rating and $7.25 target price in Friday, August 21 report. Howard Weil downgraded China Cord Blood Corp (NYSE:CO) on Friday, February 5 to “Sector Perform” rating.

According to Zacks Investment Research, “China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today. China Cord Blood Corporation collects umbilical cord blood stem cells from newborn babies, and provides laboratory testing, hematopoietic stem cell processing, and stem cell storage services.”

Insitutional Activity: The institutional sentiment decreased to 0.57 in 2016 Q2. Its down 0.08, from 0.65 in 2016Q1. The ratio fall, as 4 funds sold all China Cord Blood Corp shares owned while 10 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 6.82 million shares or 3.13% less from 7.04 million shares in 2016Q1.
Acadian Asset Mgmt Lc holds 0.02% or 713,775 shares in its portfolio. State Street holds 0% or 28,995 shares in its portfolio. Tfs Ltd has 0.02% invested in the company for 15,656 shares. First Wilshire Management holds 13,553 shares or 0.03% of its portfolio. Citigroup last reported 1.39 million shares in the company. The Pennsylvania-based Susquehanna International Group Inc Inc Llp has invested 0% in China Cord Blood Corp (NYSE:CO). Barclays Public Limited Company has 0% invested in the company for 9,400 shares. California Public Employees Retirement System accumulated 0% or 161,400 shares. The Missouri-based Counselors has invested 0.03% in China Cord Blood Corp (NYSE:CO). Advisory Research owns 46,841 shares or 0% of their US portfolio. Rock Springs Management L P holds 880,000 shares or 0.37% of its portfolio. Glg Prns Ltd Partnership has 0.16% invested in the company for 923,931 shares. Panagora Asset Mgmt, a Massachusetts-based fund reported 186,430 shares. Renaissance Ltd Limited Liability Company accumulated 749,000 shares or 0.01% of the stock. Tower Capital (Trc) reported 736 shares or 0% of all its holdings.

More notable recent China Cord Blood Corp (NYSE:CO) news were published by: which released: “News China Cord Blood Corp.CO” on January 20, 2010, also with their article: “Golden Meditech Enters into Agreements with Nanjing Xinjiekou to Sell China …” published on January 07, 2016, published: “An Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital” on March 19, 2015. More interesting news about China Cord Blood Corp (NYSE:CO) were released by: and their article: “China Cord Blood Corporation Receives Notice of Transactions Regarding its 7 …” published on August 26, 2015 as well as‘s news article titled: “China Cord Blood Corporation Announces Receipt of “Going Private” Proposal” with publication date: April 27, 2015.

CO Company Profile

China Cord Blood Corporation, incorporated on April 10, 2006, is a well-known provider of cord blood banking services in China. The Firm and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. The Firm provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Firm also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. As of March 31, 2016, the Company had three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the People’s Republic of China.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment